Copyright
©The Author(s) 2018.
World J Clin Oncol. Apr 10, 2018; 9(2): 33-41
Published online Apr 10, 2018. doi: 10.5306/wjco.v9.i2.33
Published online Apr 10, 2018. doi: 10.5306/wjco.v9.i2.33
Table 3 Association between percentage of tumor-infiltrating lymphocytes and clinical-pathological features regarding molecular subtype n (%)
| Lum A | Lum B | HER2 | TN | |||||||||
| < 50% | ≥ 50% | P value | < 50% | ≥ 50% | P value | < 50% | ≥ 50% | P value | < 50% | ≥ 50% | P value | |
| 71 | 30 | 98 | 61 | 25 | 50 | 40 | 40 | |||||
| Age (yr) | 0.181 | 0.783 | 0.624 | 0.074 | ||||||||
| Median (range) | 47 (28-75) | 47 (36-74) | 52 (28-73) | 50 (25-84) | 52 (28-66) | 49 (29-80) | 51 (26-73) | 45 (27-73) | ||||
| < 50 | 50 (70) | 17 (57) | 46 (47) | 30 (49) | 11 (44) | 25 (50) | 16 (40) | 24 (60) | ||||
| ≥ 50 | 21 (30) | 13 (43) | 52 (53) | 31 (51) | 14 (56) | 25 (50) | 24 (60) | 16 (40) | ||||
| Histological subtypes | 0.445 | 1.000 | 0.597 | 1.000 | ||||||||
| Ductal | 66 (93) | 26 (87) | 91 (93) | 57 (93) | 23 (92) | 48 (96) | 39 (98) | 38 (95) | ||||
| Lobular and others | 5 (7) | 4 (13) | 7 (7) | 4 (7) | 2 (8) | 2 (4) | 1 (3) | 2 (5) | ||||
| Histological grade | - | 0.011 | 0.514 | 0.006 | ||||||||
| G1-G2 | 69 (97) | 28 (93) | 43 (44) | 15 (25) | 9 (36) | 14 (28) | 11 (28) | 2 (5) | ||||
| G3 | 0 (0) | 0 (0) | 53 (54) | 46 (75) | 16 (64) | 35 (71) | 29 (73) | 38 (95) | ||||
| NR | 2 (3) | 2 (7) | 2 (2) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | ||||
| Tumor size (cm) | ||||||||||||
| Median (range) | 6 (3-13) | 6 (2-15) | 6 (3-20) | 7 (2-15) | 7 (3-14) | 7 (3-14) | 7 (4-24) | 7 (1-16) | ||||
| cT | 1.000 | 0.538 | 0.659 | 0.263 | ||||||||
| cT1-cT2 | 7 (10) | 3 (10) | 6 (6) | 6 (10) | 1 (4) | 4 (8) | 2 (5) | 6 (15) | ||||
| cT3-cT4 | 64 (90) | 27 (90) | 92 (94) | 55 (90) | 24 (96) | 46 (92) | 38 (95) | 34 (85) | ||||
| cN | 0.890 | 0.020 | 0.631 | 0.762 | ||||||||
| cN0 | 18 (25) | 8 (27) | 22 (22) | 5 (8) | 6 (24) | 8 (16) | 6 (15) | 7 (18) | ||||
| cN1-cN2-cN3 | 53 (75) | 22 (73) | 76 (78) | 56 (92) | 11 (44) | 27 (54) | 34 (85) | 33 (83) | ||||
| Clinical Stage | 0.666 | 0.141 | 0.742 | 0.576 | ||||||||
| EC II | 17 (24) | 6 (20) | 16 (16) | 5 (8) | 3 (12) | 8 (16) | 9 (23) | 7 (18) | ||||
| EC III | 54 (76) | 24 (80) | 82 (84) | 56 (92) | 22 (88) | 42 (84) | 31 (78) | 33 (83) | ||||
| TLCS (d) | 0.631 | 0.882 | 0.502 | 0.141 | ||||||||
| Median (range) | 64 (14-449) | 70 (19-458) | 61 (5-412) | 58 (8-285) | 68 (16-234) | 56 (11-240) | 74 (24-230) | 51 (14-982) | ||||
| Shorter than median | 34 (48) | 13 (43) | 48 (49) | 28 (46) | 12 (48) | 28 (56) | 15 (38) | 22 (55) | ||||
| Longer than median | 36 (51) | 17 (57) | 44 (45) | 27 (44) | 12 (48) | 20 (40) | 24 (60) | 18 (45) | ||||
| Missing data | 1 (1) | 0 (0) | 6 (6) | 6 (10) | 1 (4) | 2 (4) | 1 (3) | 0 (0) | ||||
| pCR | 0.054 | 0.750 | 0.150 | 1.000 | ||||||||
| No | 65 (92) | 23 (77) | 92 (94) | 56 (92) | 24 (96) | 41 (82) | 34 (85) | 34 (85) | ||||
| Yes | 6 (8) | 7 (23) | 6 (6) | 5 (8) | 1 (4) | 9 (18) | 6 (15) | 6 (15) | ||||
| Relapse | 0.450 | 0.201 | 0.737 | 0.502 | ||||||||
| No | 59 (83) | 23 (77) | 61 (62) | 44 (72) | 16 (64) | 30 (60) | 18 (45) | 21 (53) | ||||
| Yes | 12 (17) | 7 (23) | 37 (38) | 17 (28) | 9 (36) | 20 (40) | 22 (55) | 19 (48) | ||||
- Citation: Galvez M, Castaneda CA, Sanchez J, Castillo M, Rebaza LP, Calderon G, Cruz MDL, Cotrina JM, Abugattas J, Dunstan J, Guerra H, Mejia O, Gomez HL. Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World J Clin Oncol 2018; 9(2): 33-41
- URL: https://www.wjgnet.com/2218-4333/full/v9/i2/33.htm
- DOI: https://dx.doi.org/10.5306/wjco.v9.i2.33